Laboratory/Clinical Translational Research
Expression and Clinical Significance of the G1-S Modulators in Intrahepatic Cholangiocellular CarcinomaIto Y.a,b · Takeda T.a · Sasaki Y.c · Sakon M.e · Yamada T.c · Ishiguro S.d · Imaoka S.c · Tsujimoto M.f · Matsuura N.b,e
aDepartment of Surgery, Osaka Seamen’s Insurance Hospital, bDepartment of Pathology, School of Allied Health Science, Osaka University Faculty of Medicine, Departments of cSurgery and dPathology, Osaka Medical Center for Cancer and Cardiovascular Diseases, eDepartment of Surgery II, Osaka University Medical School, fDepartment of Pathology, Osaka Police Hospital, Osaka, Japan
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Objective: To elucidate the clinical roles of G1-S modulators in cholangiocellular carcinoma (CCC). Methods: We performed immunohistochemistry using antibodies against the retinoblastoma gene product (pRb), p16, p21, p27, p53 and cyclin D1 for 41 cases of CCC as well as normal bile ducts. Results: The p27 labeling index (LI) was significantly higher in cases without lymph node metastasis than in normal bile ducts, but it decreased greatly in cases with lymph node metastasis. It was inversely related to the Ki-67 LI. The p16 LI also showed a relationship with lymph node metastasis, but not with the Ki-67 LI. The p21 LI was even higher in poorly differentiated cases and showed a direct relationship with the Ki-67 LI, although it is a negative regulator of the cell cycle. pRb expression did not correlate with any clinicopathological features. Cyclin D1 overexpression was more frequently observed in cases with poor or moderate differentiation and with lymph node metastasis. Cyclin D1 overexpression and aberrant p53 expression showed direct relationships with the Ki-67 LI. Conclusions: These results suggest that in CCC: (1) p27 expression reflects the biological character of the carcinoma and may regulate its progression; (2) cyclin D1 plays a crucial role in cell cycle progression, and (3) aberrant p53 expression has some effect on CCC cell proliferating activity.
© 2001 S. Karger AG, Basel
- Sasaki K, Murakami T, Kawasaki M, Takahashi M: The cell cycle associated change of the Ki-67 reactive nuclear antigen expression. J Cell Physiol 1987;133:579–584.
- Pardee AB: G1 events and regulation of cell proliferation. Science 1989;246:603–608.
- Friend SH, Bernards R, Rogelj S, Weinberg RA, Rapaport JM, Albert DM, Dryjia TP: A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteoarcoma. Nature 1986;323:643–646.
- Chellappan SP, Hiebert S, Mudryj M, Horowitz JM, Nevens JR: The E2F transcription factor is a cellular target for the RB protein. Cell 1991;65:1053–1061.
- Lees JA, Buchkovich KJ, Marshak DR, Anderson CW, Harlow E: The retinoblastoma protein is phosphorylated on multiple sites by human cdc2. EMBO J 1991;10:4279–4290.
- Mittnacht S, Lees JA, Desai D, Harlow E, Morgan DO, Weinberg RA: Distinct sub-populations of the retinoblastoma protein show a distinct pattern of phosphorylation. EMBO J 1994;13:118–127.
- Motokura T, Bloom T, Kim HG, Juppner H, Ruderman JV, Kronenbereg HM, Arnold A: A novel cyclin encoded by a bcl1-linked candidate oncogene. Nature 1991;350:512–515.
- Motokura T, Keyomarsi K, Kronenberg HM, Arnold A: Cloning and characterization of human cyclin D3, a DNA closely related in sequence to the PRAD1/cyclin D1 proto-oncogene. J Biol Chem 1992;267:20412–20415.
- Quelle DE, Ashmun RA, Shurtleff SA, Kato JY, Bar-Sagi D, Roussel MF, Sherr CJ: Overexpression of mouse D-type cyclins accelerates G1 phase in rodent fibroblasts. Genes Dev 1993;7:1559–1571.
- Matsushime H, Ewen ME, Strom DK, Kato JY, Hanks SK, Roussel MF, Sherr CJ: Identification and properties of an atypical catalytic subunit (p34PSK-J3/cdk4) for mammalian D type G1 cyclins. Cell 1992;71:323–334.
Serrano M, Hannon GJ, Beach D: A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 1993;366:705–707.
- Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D: p21 is a universal inhibitor of cyclin kinases. Nature 1993;366:701–704.
- Polyak K, Lee MH, Erdjument-Bromage A, Koff A, Roberts JM, Tempst P, Massague J: Cloning of p27Kip1, a cycli-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 1994;78:59–66.
- Mori T, Miura K, Aoki T, Nishihara T, Mori S, Nakamura Y: Frequent somatic mutation of the MTS1/CDK4I (multiple tumor suppressor/cyclin-dependent kinase 4 inhibitor) gene in esophageal squamous cell carcinoma. Cancer Res 1994;54:3396–3397.
- Spruck CH III, Gonzalez-Zulueta M, Shibata A, Simoneau AR, Lin MF, Gonzales F, Tsai YC, Jones PA: p16 gene in uncultured tumours. Nature 1994;370:183–184.
- Kees UR, Ranford PR, Hatzis M: Deletions of the 16 gene in pediatric leukemia and corresponding cell lines. Oncogene 1996;12:2235–2239.
- Zhou X, Tarmin L, Yin J, Jiang HY, Suzuki H, Rhyu MG, Abraham JM: The MTS1 gene is frequently mutated in primary human esophageal tumors. Oncogene 1994;9:3737–3741.
- Merlo A, Herman JG, Mao L, Gabrielson E, Burger PC, Baylin SB, Sideransky D: 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat Med 1995;1:686–692.
- Shiohara M, El-Deiry WS, Wada M, Nakamaki T, Takeuchi S, Yang R, Chen DL, Vogelstein B, Koeffler HP: Absence of WAF1 mutations in a variety of human malignancies. Blood 1994;84:3781–3784.
- Ito Y, Matsuura N, Sakon M, Takeda T, Umeshita K, Nagano H, Nakamori S, Dono K, Tsujimoto M, Nakahara M, Nakao K, Monden M: Both cell proliferation and apoptosis significantly predict shortened disease-free survival in hepatocellular carcinoma. Br J Cancer 1999;81:747–751.
- Ito Y, Matsuura N, Sakon M, Miyoshi E, Noda K, Takeda T, Umeshita K, Nagano H, Nakamori S, Dono K, Tsujimoto M, Nakahara M, Nakao K, Taniguchi N, Monden M: Expression and prognostic roles of the G1-S modulators in hepatocellular carcinoma: p27 independently predicts the recurrence. Hepatology 1999;30:90–99.
- Nakeeb A, Pitt HA, Sohn TA, Coleman J, Abrams RA, Piantadosi S, Hruban RH, Lillemoe KD, Yeo CJ, Cameron JL: Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumors. Ann Surg 1996;224:463–475.
Craig JR, Peters RL, Edmonson HA: Tumors of the Liver and Intrahepatic Bile Ducts. Washington, Armed Forces Institute of Pathology, 1989.
Liver Cancer Study Group of Japan: The General Rule of the Clinical and Pathological Study of Primary Liver Cancer, ed 3. Tokyo, Kanehara Press, 1992.
- Pagano M, Tam SW, Theodoras AM, Beer-Romero P, Del Sal G, Chau V, Yew PR, Draetta GF, Rolfe M: Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 1995;269:682–685.
- Fredersdorf S, Burns J, Milne AM, Packham G, Fallis L, Gillett CE, Royds JA, Peston D, Hall PA, Hanby AM, Barnes DM, Shousha S, O’Hare MJ, Lu X: High level expression of p27(kip1) and cyclin D1 in some human breast cancer cells: Inverse correlation between the expression of p27(kip1) and degree of malignancy in human breast and colorectal cancers. Proc Natl Acad Sci USA 1997;94:6380–6385.
- Hui A-M, Cui X, Makuuchi M, Li X, Shi Y-Z, Takayama T: Decreased p27kip1 expression and cyclin D1 overexpression, alone and in combination, influence recurrence and survival of patients with resectable extrahepatic bile duct carcinoma. Hepatology 1999;30:1167–1173.
- Charlotte F, L’Hermine A, Martin N, Geleyn Y, Nollet M, Gaulard P, Zafrani ES: Immunohistochemical detection of bcl-2 protein in normal and pathological human liver. Am J Pathol 1994;144:460–465.
- Ito Y, Miyoshi E, Takeda T, Sakon M, Tsujimoto M, Matsuura N: ets-1 expression in extrahepatic bile duct carcinoma and cholangiocellular carcinoma. Oncology 2000;58:248–252.
- Diamantis I, Karamitopoulou E, Perentes E, Zimmermann A: p53 protein immunoreactivity in extrahepatic bile duct and gallbladder cancer: Correlation with tumor grade and survival. Hepatology 1995;22:774–779.
- Hui AM, Sakamoto M, Kanai Y, Ino Y, Gotoh M, Yokota J, Hirohashi S: Inactivation of p16INK4 in hepatocellular carcinoma. Hepatology 1996;24:575–579.
- Yoshida S, Todoroki T, Ichikawa Y, Hanai S, Suzuki H, Hori M, Fukao K, Miwa M, Uchida K: Mutations of p16Ink4/CDKN2 and p15Ink4B/MTS2 genes in biliary tract cancer. Cancer Res 1995;55:2756–2760.
- Shapiro GI, Park JE, Edwards CD, Mao L, Merlo A, Sidransky D, Ewen ME, Rollins BJ: Reciprocal Rb inactivation and p16INK4 expression in primary lung cancer and cell lines. Cancer Res 1995;55:505–509.
- Aaltomaa S, Lipponen P, Eskelinen M, Ala-Opas M, Kosma VM: Prognostic value and expression of p21 (waf1/cip1) protein in prostate cancer. Prostate 1999;39:8–15.
- Caffo O, Doglioni C, Veronese S, Bonzanini M, Marchetti A, Buttitta F, Fina P, Leek R, Morelli L, Palma PD, Harris AL, Barbareschi M: Prognostic value of p21 (WAF1) and p53 expression in breast carcinoma: An immunohistochemical study in 261 patients with long-term follow-up. Clin Cancer Res 1996;2:1591–1599.
- Gomyo Y, Ikeda M, Osaki M, Tatebe S, Tsujitani S, Ikeguchi M, Kaibara N, Ito H: Expression of p21 (waf1/cip1/sdi1), but not p53 protein, is a factor in the survival of patients with advanced gastric carcinoma. Cancer 1997;79:2067–2072.
- Anttila MA, Kosma VM, Hongxiu J, Puolakka J, Juhola M, Saarikoski S, Syrjanen K: p21/WAF1 expression as related to p53, cell proliferation and prognosis in epithelial ovarian cancer. Br J Cancer 1999;79:1870–1878.
- Baas IO, Mulder JWR, Johan G, Offerhaus A, Vogelstein B, Hamilton SR: An evaluation of six antibodies for immunohistochemistry of mutant p53 gene product in archival colorectal neoplasms. J Pathol 1994;172:5–12.
- Okuda T, Hirohashi K, Kinoshita H, Wakasa K, Sakurai M: Characteristic histologic features of human hepatocellular carcinoma with mutant p53 protein. World J Surg 1996;20:215–220.
- Nakopoulou L, Janinins J, Giannopoulou I, Lazaris AC, Koureas A, Zacharoulis D: Immunohistochemical expression of p53 protein and proliferation cell nuclear antigen in hepatocellular carcinoma. Pathol Res Pract 1995;191:1208–1213.
- Wakasugi E, Kobayashi T, Tamaki Y, Ito Y, Miyashiro I, Komoike Y, Takeda T, Shin E, Takatsuka Y, Kikkawa N, Monden T, Monden M: p21(WAF1/CIP1) and p53 protein expression in breast cancer. Am J Clin Pathol 1997;107:684–691.
- Ito Y, Kobayashi T, Takeda T, Komoike Y, Wakasugi E, Tamaki Y, Tsujimoto M, Matsuura N, Monden M: Expression of p21(WAF1/CIP1) protein in clinical thyroid tissues. Br J Cancer 1996;74:1269–1274.
- Zhang X, Xu H-J, Murakami Y, Sachse R, Yashima K, Hirohashi S, Hu S-X, Benedict WF, Sekiya T: Deletions of chromosome 13q, mutations in Retinoblastoma 1, and retinoblastoma protein state in human hepatocellular carcinoma. Cancer Res 1994;54:4177–4182.
- Ishikawa T, Furihata M, Ohtsuki Y, Murakami H, Inoue A, Ogoshi S: Cyclin D1 overexpression related to retinoblastoma protein expression as a prognostic marker in human oesophageal squamous cell carcionoma. Br J Cancer 1998;77:92–97.
- Meada K, Chung Y, Kang S, Ogawa M, Onoda N, Nishiguchi Y, Ikehara T, Nakata B, Okuno M, Sowa M: Cyclin D1 overexpression and prognosis in colorectal adenocarcinoma. Oncology 1998;55:145–151.
Caputti M, De Luca L, Papaccio G, D’Aponta A, Cavallotti I, Scala P, Scarano F, Monna M, Gualdiero L, De Luca B: Prognostic role of cyclin D1 in non small cell lung cancer: An immunohistochemical analysis. Eur J Histochem 1997;41:133–138.
- Nishida N, Fukuda Y, Komeda T, Kita R, Sando T, Furukawa M, Amenomori M, Shibagaki I, Nakao K, Ikenaga M: Amplification and overexpression of the cyclin D1 gene in aggressive human hepatocellular carcimona. Cancer Res 1994;54:3107–3110.
- Gillett C, Fantl V, Smith R, Fisher C, Bartek J, Dickson C, Barnes D, Peters G: Amplification and overexpression of cyclin D1 in breast cancer detected y immunohistochemical staining. Cancer Res 1994;54:1812–1817.
- Jiang W, Zhang YJ, Kahn SM, Hollstein MC, Santella RM, Lu SH, Harris CC, Montesano R, Weinstein IB: Altered expression of the cyclin D1 and retinoblastoma genes in human esophageal cancer. Proc Natl Acad Sci USA 1993;90:9026–9030.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.